# OnCo record cml (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/cml/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "cml" ;
  schema:name "Chronic myeloid leukaemia (CML)"@en ;
  schema:description "Chronic myeloid leukaemia is a blood cancer driven by a single fused gene, BCR-ABL1, and the model for oncogene-targeted treatment: imatinib in 2001 and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term. About half of patients with a sustained deep molecular response can now stop treatment altogether."@en ;
  schema:url <https://onco.cc/cancers/cml/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia> ;
  owl:sameAs <http://www.wikidata.org/entity/Q729735> ;
  schema:citation <https://www.nature.com/articles/s41375-020-0776-2>, <https://www.cancer.gov/types/leukemia/patient/cml-treatment-pdq>, <https://seer.cancer.gov/statfacts/html/cmyl.html> ;
  onco:tag "gap-fill", "haematologic" ;
  onco:related <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/cmml/>, <https://onco.cc/cancers/aml/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/cytogenetics-fish/> ;
  onco:targets <https://onco.cc/targets/bcr-abl/> ;
  onco:drugs <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/dasatinib/>, <https://onco.cc/drugs/nilotinib/>, <https://onco.cc/drugs/bosutinib/>, <https://onco.cc/drugs/ponatinib/>, <https://onco.cc/drugs/asciminib/>, <https://onco.cc/drugs/busulfan/>, <https://onco.cc/drugs/omacetaxine/> ;
  onco:companies <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/takeda/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/cml-signalling/> ;
  onco:terms <https://onco.cc/terms/oncogene-addiction/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/resistance/> ;
  onco:trials <https://onco.cc/trials/nct04971226/>, <https://onco.cc/trials/nct03459534/>, <https://onco.cc/trials/nct05456191/>, <https://onco.cc/trials/dasision/> ;
  onco:journals <https://onco.cc/journals/leukemia-research/> ;
  onco:pipeline <https://onco.cc/drugs/asciminib/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/radotinib/> ;
  onco:standardOfCare <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/dasatinib/>, <https://onco.cc/drugs/nilotinib/>, <https://onco.cc/drugs/bosutinib/>, <https://onco.cc/drugs/asciminib/>, <https://onco.cc/drugs/ponatinib/>, <https://onco.cc/drugs/asciminib/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/bosutinib/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/drugs/ponatinib/>, <https://onco.cc/drugs/dasatinib/>, <https://onco.cc/technologies/allogeneic-hsct/> .